Mitral valve disease in dogs and pet insurance: the bill at each ACVIM stage and the clauses that meet it

Four ACVIM stages, four different kinds of claim

The 2019 consensus, written by a ten-member panel and first-authored by Bruce Keene of North Carolina State University, sorts the disease into stages so that treatment can follow severity. Stage A is a dog at high risk with no structural change yet; the panel's own example is "every Cavalier King Charles Spaniel or other predisposed breed without a heart murmur." Stage B is structural disease without signs of heart failure, split into B1 and B2. Stage C is current or past heart failure. Stage D is heart failure that no longer responds to standard treatment.

For insurance, the useful fact is that each stage produces a different kind of bill, and each kind of bill is tested by a different clause. The table sets the consensus recommendations beside the invoice lines they create. The recommendations are summarized for insurance education; the stage a particular dog is in is a judgment for its veterinarian or cardiologist.

Two details in the B2 row matter to a claim file. The consensus says that ideally all four criteria are met before treatment starts "because treatment represents a lifelong commitment," so the move from B1 to B2 is usually documented by an echocardiogram report with measurements. That report becomes the paper trail an adjuster reads. And the consensus says a dog that has once been in stage C stays in stage C even after its signs resolve, except in the rare dog whose valve is surgically repaired. In policy terms, nothing about this disease is "cured," which is why the cured-condition clauses in the sample forms, Spot's 180 days and Figo's 12 months free of treatment and symptoms, do not rescue a mitral valve record.

What the drug labels put on the invoice

Three medicines dominate the cost lines, and their FDA labels on DailyMed explain why the monthly bill differs between dogs. They appear here as cost lines only; a dog's prescription is set by its veterinarian.

Pimobendan is sold as Vetmedin, Boehringer Ingelheim's chewable tablet (NADA 141-273), in 1.25, 2.5, 5 and 10 mg strengths, 50 tablets to a bottle. The current label, revised November 2025 and posted to DailyMed in April 2026, carries two indications: delaying the onset of congestive heart failure in dogs with stage B2 preclinical MMVD, and managing the signs of heart failure from MMVD or dilated cardiomyopathy. The total daily dose is set by weight, 0.23 mg per pound, split into two portions about 12 hours apart. A 5-pound Chihuahua and a 20-pound Dachshund on the same diagnosis therefore buy very different quantities of the same drug, and the medication line on the invoice scales roughly with body weight. A separate product, Vetmedin-CA1, carries the same B2 indication under a conditional approval (application 141-556), on a label posted in September 2024.

Generic pimobendan chewables now exist. The Cronus Pharma label (ANADA 200-728, revised April 2026) lists only the heart failure indication, not the B2 one. That difference matters less to the sample policies than an owner might fear: Spot's sample covers "prescription medications prescribed by a veterinarian and approved by the Food and Drug Administration," and Figo's defines medication as one "prescribed by a Veterinarian and approved by the Food and Drug Administration." Neither form, as written, asks whether the drug is approved for the stage it is used at. If the clinic dispenses a generic at stage B2, it is still worth asking the insurer in writing whether it treats an approved drug used outside its labeled indication the same way.

The Vetmedin label also explains why a covered B2 dog can stay in the cheaper rung for a long time. In the label's main B2 study, 363 dogs aged 6 to 17 and weighing 9 to 33 pounds were randomized. Median time to confirmed heart failure was 1,231 days in the pimobendan group against 806 days in the control group, a difference of 425 days, or 14.2 months. For a policy, that is roughly an extra policy year in which the claim is a monthly prescription and a recheck rather than an emergency admission. It is a population median, not a promise about any one dog.

Annual deductible, per-condition deductible and the annual cap, stage by stage

The same four years run through three common policy shapes. Structure A has a $250 annual deductible, 80 percent reimbursement and a $5,000 annual limit. Structure B has a $500 annual deductible, 90 percent reimbursement and no annual limit. Structure C has a $250 deductible paid once per condition, 90 percent reimbursement and no annual limit. Payment is figured as the bill, minus any deductible due that year, times the reimbursement rate, then capped at the limit. The example assumes every line is covered and that no other claim used the deductible in the same year; premiums are left out because they differ by insurer, age and location.

Three things decide the gap. In the B1 year the bill barely clears a deductible, and under Structure B the owner gets back $158 of $675, so a murmur year can feel like the insurance is not working when it is simply sitting below the deductible. The cap then bites in the heart-failure years: Structure A pays $5,000 in each of years 3 and 4, where the uncapped arithmetic gives $5,024 and $5,800, so the limit alone costs the owner $824 over those two years, and the owner's share in year 4 reaches $2,500. And a per-condition deductible gets better the longer a chronic disease runs, because years 2 to 4 carry no deductible at all.

None of this makes one shape the right purchase. A per-condition deductible can work against an owner whose dog has several unrelated small claims each year, and an unlimited policy usually carries a higher premium. The deductible and limits decoder runs the general mechanics, and CalculatorVillage's percentage calculator handles the reimbursement arithmetic for a different bill. What this disease adds is a timeline: the expensive years arrive late, often when the dog is 9 or older, so the limit and deductible terms that matter most are the ones in force at renewal years from now, not on the day of purchase.

The heart diet: the line most likely to come back unpaid

The consensus recommends dietary treatment from stage B2: "mild dietary sodium restriction and provision of a highly palatable diet with adequate protein and calories" (Class IIa, weak evidence), with dietary management continuing into stages C and D. When a clinic prescribes a therapeutic cardiac food, that becomes a monthly line of its own, and five sample policies split five different ways on it.

The deciding words are "sole treatment." Two forms pay for a prescription food only when it is the only treatment, and a B2 dog's food is prescribed alongside pimobendan, not instead of it. A third form pays only while the illness is symptomatic, and a B2 dog by definition has no signs of heart failure.

In the example, the diet line adds $720 a year for three years, $2,160 in all. Under the Figo and AKC wording that whole amount most likely stays with the owner; under the MetLife wording it would run through the deductible and reimbursement like any other covered line. The Trupanion form is older than the others and is the posted 2011 version, so a current form may differ. The prescription food wording sits in a different part of each policy from the heart coverage, which is why owners who check only the illness list are surprised by it.

Murmur first, diagnosis later: the dates an adjuster reads

The pre-existing question works for dog hearts much as it does for cats with HCM, and the cat HCM guide walks through the murmur and "detectable" clauses in detail. For MMVD, the date that matters is the first time a murmur or other heart sign appears in any record, not the date of the echocardiogram that confirms it. Spot's sample defines when a condition occurs as when signs "first were observed by any individual, recorded in your pet's medical record, or would have been detectable by a routine physical veterinary exam." The NAIC Pet Insurance Model Act (#633) defines a preexisting condition around veterinary advice, previous treatment or signs before the effective date or during a waiting period, and puts "the burden of proving that the preexisting condition exclusion applies" on the insurer.

The gap between a murmur and a diagnosis is large in real records. In the VetCompass study of 111,967 dogs at 93 English primary-care practices (Mattin and colleagues, Journal of Veterinary Internal Medicine, 2015), 405 dogs had a diagnosed degenerative mitral valve disease and a further 3,557 had a murmur consistent with it but no recorded diagnosis. Roughly nine murmur notes sat in records for every formal diagnosis. Each of those notes is a date. Insured dogs in the same study had higher odds both of a recorded murmur (odds ratio 1.25) and of a diagnosis (3.56), which fits the plain point that dogs seen more often generate more paper.

Two clauses soften the timing for an insured dog. The Model Act says "a condition for which coverage is afforded on a policy cannot be considered a preexisting condition on any renewal of the policy," so a murmur first noted in year three of a continuous policy stays covered at every later renewal. And Figo's sample sets the baseline differently for a dog without an exam in the 12 months before the start date: "the first documented veterinary examination after the effective date" is used to judge pre-existing conditions. A clean, dated exam before enrollment is the record that protects a predisposed breed. The general rules are in the pre-existing conditions guide, and the waiting periods guide lays out how long the gap before illness cover runs.

Cavalier, Chihuahua, Dachshund and Miniature Schnauzer in the references

Breed lists for this disease are often repeated without a source. The table shows exactly what four references say about the four breeds, including where the evidence is weaker than the lists suggest. The odds ratios come from the multivariable model in the VetCompass study and compare each breed with crossbred dogs; an interval that includes 1.0 means the study could not separate that breed's risk from the crossbred baseline.

The Cavalier stands apart on every measure. Its odds in the English data were about 47 times those of crossbreds, and the consensus notes the breed develops the disease young, although its progression to heart failure "does not appear to be markedly different" from other breeds. For insurance that means a Cavalier's murmur can arrive during the years when many owners are still deciding whether to keep a puppy policy. The Chihuahua's elevated odds are statistically clear in the same data. The Dachshund is named as predisposed by both clinical references, but the English primary-care sample did not show a clear excess, and the Miniature Schnauzer's case rests mainly on its appearance among enrolled breeds in the drug trial. All four are small dogs, and the consensus says prevalence is higher in dogs under 20 kg.

The anchors are the breed pages' published research figures, reviewed October 4, 2026, and they are samples to judge a quote against, not prices for any dog. Set against them, the example's stage C year of $6,530 is more than ten years of the Cavalier's $54 anchor ($648 a year). That comparison is scale, not a forecast, and a live quote for your own dog is the only real number.

One more record to know about: the Orthopedic Foundation for Animals cardiac database. OFA says a dog found normal at 12 months or older receives a registry number, that evaluations are valid for 1 year because acquired heart disease can develop later, and that annual exams are recommended. Its Advanced Cardiac certification requires an echocardiogram for every breed. A breeder's clearance on the parents is useful context, but it is not the puppy's own record, and only the puppy's dated exams count for the policy.

Hospital nights in stages C and D, and when a second problem is called related

The jump in the example from $1,960 to $6,530 is mostly one event. The consensus describes acute stage C care as furosemide 2 mg/kg by injection, repeated hourly until breathing improves or a total of 8 mg/kg has been given over 4 hours, with oxygen supplementation if needed, pimobendan and close monitoring; some dogs need more aggressive support such as afterload reducers or temporary ventilatory assistance. These are emergency and hospitalization lines, and they tend to arrive at night. The emergency vet visit cost guide covers how those invoices are built, including the separate emergency exam fee that some policies pay and some do not; the exam fee guide shows the wording.

Stage D adds a different risk: the policy may group new problems with the heart claim. The consensus says at least 30 percent of cases also involve the tricuspid valve, and stage D can bring pulmonary hypertension, ascites and kidney strain from diuretics. Under a per-condition limit or deductible, whether those are the same condition decides the payment. Spot's sample counts conditions "related to, secondary, or resultant from" a pre-existing condition as pre-existing too, and MetLife's Ohio sample excludes "complications of conditions or procedures that are not otherwise covered by this Policy." For a covered heart, grouping usually helps on a per-condition deductible and hurts on a per-condition limit. Ask which applies before the second diagnosis is written.

Surgery is the outlier. The consensus says mitral valve repair is available at "the few centers demonstrating evidence of acceptably low complication rates," recommended by some panelists in advanced B2, described as benefiting stage C dogs at centers with low complication rates, and associated with higher perioperative mortality at stage D. Few of the sample forms name heart surgery at all; they cover surgery as a category, subject to the annual limit. On Structure A in the example, one surgical admission would meet a $5,000 cap on its own, so an owner considering a referral center should read the limit, not the surgery list.

Five heart records, from a clean puppy exam to a renewal in heart failure

The date of the first murmur sorts small-breed owners into five positions, set out below. None of them predicts an insurer's decision on a particular dog.

The insurer's answers that would have changed the Cavalier's numbers

Mitral valve claims are decided in definitions far from the heading that says illnesses are covered. Six questions reach them, each tied to a line of the 15-pound Cavalier example.

1. Is mitral valve disease covered for this breed, or excluded anywhere as hereditary, congenital or breed-specific? The hereditary exclusions guide shows the wording to look for.
2. Is the deductible annual or per condition, and does a heart condition diagnosed this year keep that treatment at renewal?
3. What is the annual limit, and is there a separate per-condition or lifetime cap on cardiac care?
4. Does the medication definition cover an FDA-approved drug used outside its labeled stage, such as a generic pimobendan at stage B2?
5. Is a prescription cardiac diet covered when it is given alongside medication rather than as the sole treatment?
6. If tricuspid valve disease, pulmonary hypertension or kidney changes are diagnosed later, are they grouped with the mitral valve claim?

Owners of a predisposed breed can put the same questions to any insurer before buying, and the answers are easiest to compare on paper. For the breed most exposed to this disease, the Cavalier King Charles Spaniel page sets its other inherited conditions, syringomyelia among them, beside the heart, which matters because they can share the same annual limit. More condition guides are in the conditions hub, and the senior dog guide covers the age when stage C usually arrives.